Genetic testing has had a shift in the past ten years, as it has left medical laboratories and entered living rooms.
Myriad Genetics (MYGN) announced MyRisk Hereditary Cancer Test-the gold standard in germline testing-has been expanded to include genes referenced ...
These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The ...
SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...
In the United States, 1 in every 250 people has inherited a genetic variant that leads to dangerously high cholesterol levels ...
Millions struggle with depression and anxiety, often enduring long waits for effective treatment. Scientists in Sweden, ...
Patients with kidney disease are largely unaware of genetic testing opportunities, according to data presented at ASN Kidney ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback